Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,231 across all filing types
Latest filing 2025-01-06 Director's Dealing
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
113年12月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, chairman, general manager, and their related parties. It includes specific data on shares held, increases, decreases, and trust shares. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full financial report, earnings release, or regulatory announcement of a report. The document is not a proxy statement or voting result announcement. Given the detailed insider shareholding data, this fits the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades).
2025-01-06 Chinese
113年12月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders, including directors, supervisors, and senior management, showing their current holdings, pledged shares, and related information. It is focused on insider shareholdings and changes, with no financial statements or earnings data. The content matches the description of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is over 5,000 characters and contains substantive data on insider holdings, not just an announcement or certification. Therefore, the appropriate classification is Director's Dealing (DIRS).
2025-01-06 Chinese
113年第3季財務報告書 — 202401_1789_AIA.pdf
Regulatory Filings
2024-12-23 Chinese
113年第3季財務報告書 — 202401_1789_AI1.pdf
Regulatory Filings
2024-12-23 Chinese
113年第3季財務報告書 — 202404_1789_AIC.pdf
Audit Report / Information Classification · 95% confidence The document is titled 'Parent Company Only Financial Statements and Independent Auditors’ Report' for the years ended December 31, 2024 and 2023. It contains detailed financial statements including balance sheets, statements of comprehensive income, changes in equity, cash flows, notes to the financial statements, and an independent auditor's report. The auditor's report includes an opinion, basis for opinion, key audit matters, responsibilities of management and auditors, and other standard audit report sections. The document is comprehensive, contains substantive financial data and analysis, and is clearly a standalone audit report with financial statements. It is not merely an announcement or a certification letter. Therefore, it fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles, excluding full annual reports. The document is not a full Annual Report (10-K) as it only covers parent company financials and audit report, not the full company activity and performance. Hence, the correct classification is AR with high confidence.
2024-12-23 Chinese
113年第3季財務報告書 — 202404_1789_AIA.pdf
Annual Report Classification · 100% confidence The document is titled 'Consolidated Financial Statements and Independent Auditors’ Report December 31, 2024 and 2023' for ScinoPharm Taiwan, Ltd. It contains detailed consolidated financial statements including balance sheets, statements of comprehensive income, changes in equity, cash flows, and extensive notes. It also includes an independent auditor's report with an opinion, basis for opinion, key audit matters, and auditors' responsibilities. The document is comprehensive, covering full financial performance and audit results for the fiscal years ending December 31, 2024 and 2023. This matches the definition of an Annual Report (10-K) which covers company activity and full financial performance. The document is not a short announcement or a certification letter, but a full financial report with substantive financial data and analysis.
2024-12-23 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.